Most applications of xMAP™ (Luminex ® ) bead-based assay technology in diagnostics and drug discovery use immobilized antigens or antibodies. Here the authors describe the development of novel assay systems in which synthetic oligonucleotides that specifically bind and inhibit other biomolecules-so-called aptamers-are directly immobilized on beads. The robustness, specificity, and sensitivity of aptamer-based assays were demonstrated in a test system that detected human α-thrombin in serum samples. xMAP technology was also adapted to competitive screening formats where an aptamer/protein complex was disrupted by a functionally analogous competitor. The results indicate that such assays are excellently suited for diagnostic applications or drug screening, where aptamers serve as competitive binding probes for the identification of small-molecule hits. These methods should be transferable to a large number of applications because specific aptamers can be rapidly generated for almost any protein target. (Journal of Biomolecular Screening 2006:773-781) 
INTRODUCTION
A PTAMERS ARE SHORT SINGLE-STRANDED OLIGONU-CLEOTIDES, of either RNA or DNA, that can adopt a wide variety of 3-dimensional conformations, enabling them to bind specifically to target molecules with high affinity. They recognize their targets by complementary shape interactions and favor grooves and clefts as binding sites. 1 Because protein active sites are often buried deep inside the molecule, this mode of recognition means that aptamers are specific ligands with high inhibitory potential. 2, 3 Aptamers can be rapidly isolated from randomized oligonucleotide libraries of ~10 15 different sequences by an in vitro selection procedure termed SELEX (Systematic Evolution of Ligands by EXponential enrichment), which has been recently automated. [4] [5] [6] High-affinity aptamers for almost any target (e.g., whole cells, viruses, proteins, peptides, and organic molecules) can be enriched by iterative cycles of 1) binding to the target, 2) removing nonbinding sequences, and 3) enzymatic amplification of the remaining binders.
Aptamers have been used for various diagnostic assays, affinity chromatography procedures, and even for therapeutic applications. [7] [8] [9] [10] [11] Other promising applications of aptamers are their uses as tools in target validation and drug discovery, where their high inhibitory potential and rapid generation qualify them for functional validation of targets from genomic and proteomic research. They act directly on the proteomic level by targeting specific protein sites, domains, or even posttranslational modifications. 6, 12, 13 They therefore provide valuable alternatives to the common genetic knockout or knock-down strategies (e.g., RNAi), where the function of a protein is investigated by reducing its overall expression. Aptamers can also be integrated into competitive high-throughput screening (HTS) assays for small molecules that bind to the same functional site and displace the aptamer from its target. 14, 15 This aptamer-based approach is especially attractive for orphan targets for which no ligands or substrates have been identified or for which a functional assay is not available.
xMAP technology has become a well-established method used in diagnostic research. It is based on quantifying the interaction between immobilized capture molecules and target molecules. The interactions take place on the surface of polystyrene beads and are quantified using fluorescently labeled targetspecific detection molecules. Each bead type carries a unique color code that is derived from a distinct mixture of 2 dyes. For assay multiplexing, up to 100 different bead types, each with a different color and specific for a different analyte, can be assayed simultaneously in a single sample. Beads are simultaneously interrogated in a fluid stream by 2 lasers: a green laser that excites detection molecule fluorescence and a red laser that excites bead color-coded fluorescence. Background from free detection molecules is excluded by only recording detection signals that contain both detection (green) and bead-color (red) fluorescence components. After a certain number of beads are counted, the fluorescence signal is deconvoluted to assign the measured detection of fluorescence to the corresponding bead spectral address.
Adapting aptamer technology to the xMAP platform greatly expands its usefulness in drug screening. In this study, we demonstrate capture of α-thrombin from human serum and an aptamerbased assay for the identification of α-thrombin inhibitors. In a second model system using HIV-1 Rev, we demonstrate the feasibility of using aptamer-xMAP technology for compression screening assays to identify small-molecule inhibitors.
MATERIALS AND METHODS

Aptamers
An antithrombin DNA aptamer (DNA15, 5´-GGTTGGTGTG-GTTGG-3´) 16 was obtained from Operon GmbH (Cologne, Germany). An anti-HIV-Rev RNA aptamer (RBE, 5´-GGGAG-GUGGGCGCAGUUCGCUGACGGUACACC-3´) 17, 18 was synthesized by Dharmacon (Lafayette, LA). To enable immobilization on beads, both aptamers were also synthesized with 5´-end amino groups and a C7 (DNA15) or C6 spacer (RBE).
Coupling of aptamers to carboxylated microbeads
LiquiChip Carboxy Beads (QIAGEN GmbH, Hilden, Germany) were used to immobilize aptamers. Carboxyl groups on the surface of LiquiChip Carboxy Beads allow covalent attachment of aptamer amino groups after activation using N-(3-dimethylaminopropyl)-N´-ethylcarbodiimide (EDC). For each aptamer coupling procedure, a 125-µL aliquot (2.5 × 10 6 beads) was transferred into a microcentrifuge tube and centrifuged for 3 min at 10,000 × g. The supernatant was carefully removed and discarded. The bead pellet was resuspended in 50 µL 0.1 M MES (pH 5.0) and vortexed thoroughly for 30 sec. After resuspension, 1 nmol (1 µL of a 1-mM solution) of an amino-substituted aptamer was added and mixed briefly. For activation of the bead surface, 10 µL of freshly prepared EDC solution (50 mg/mL in water) was added and mixed briefly. The coupling reaction was incubated for 2 h in the dark at room temperature (RT) with gentle agitation. After incubation, the beads were centrifuged for 3 min at 10,000 × g at RT. The supernatant was carefully removed and discarded. The bead pellet was washed with 1 mL phosphate-buffered saline (PBS), 0.02% Tween-20, and then resuspended in 125 µL PBS, 0.02% Tween-20.
Biotinylation of target proteins
Human α-thrombin was purchased from CellSystems (St. Katharinen, Germany). HIV-Rev was provided by NascaCell Technologies AG (Munich, Germany). To enable detection of proteins that bound to the appropriate aptamer capture beads, human α-thrombin and HIV-Rev were biotinylated using EZlink Sulfo-NHS-LC-Biotin from Pierce (Rockford, IL). Then, 100 µg human α-thrombin was incubated with a 5-fold molar excess of Sulfo-NHS-LC-biotin in a total volume of 100 µL PBS for 30 min at 4 °C, followed by an additional incubation step at RT for 30 min. Excess NHS-biotin was removed by gel filtration using a Micro Bio-Spin-Chromatography column from Biorad, Inc. (Hercules, CA) according to the manufacturer's instructions. For the biotinylation of HIV-Rev, 100 µg protein was incubated with a 12-fold molar excess of Sulfo-NHS-LC-biotin in a total volume of 100 µL of 50 mM NaH 2 PO 4 and 1 M NaCl (pH 8.0) for 30 min at 4 °C, followed by an incubation for 30 min at RT. Excess NHS-biotin was removed by dialysis (MWCO 3500 Da) against 50 mM NaH 2 PO 4 and 1 M NaCl (pH 8.0) for 3.5 h at 4 °C.
Protein-aptamer binding assays
Assays using α-thrombin were performed in thrombin binding buffer (PBS, 0.1% [w/v] bovine serum albumin [BSA]). All incubation steps were performed in the dark at RT with agitation at 600 rpm on a microplate shaker. To demonstrate binding of thrombin to the DNA15 aptamer, increasing amounts of biotinylated α-thrombin (0-25 nM) were incubated with 2000 DNA15-coated LiquiChip Carboxy Beads in a total volume of 70 µL thrombin binding buffer for 1 h. Subsequently, 200 ng (10 µL) streptavidin-Rphycoerythrin (SAPE, Molecular Probes, Eugene, OR) was added and the reaction incubated for 1 h. The amount of captured target protein was analyzed using a LiquiChip Reader and LiquiChip software version 2.3 (QIAGEN GmbH, Hilden, Germany).
Formation and detection of HIV-Rev-aptamer complexes was performed in the same manner as described for thrombin using RBE-coated LiquiChip Carboxy Beads, biotinylated HIV-Rev-protein (0-50 nM), and Rev binding buffer (50 mM Tris; 137 mM KCl;
Competition assays
DNA15-coated beads were incubated with biotinylated human α-thrombin (6.25 nM) in the presence of increasing amounts of human serum (0%-10%), hirudin fragment 54-65 (0-60 µM) (Sigma-Aldrich, St. Louis, MO), or free DNA15 (0-1000 nM) for 1 h in the dark in a total volume of 70 µL in thrombin binding buffer. The fraction of protein bound to the aptamer-coated beads was detected using SAPE as described above. Then, 100 ng SAPE was used in the case of α-thrombin and 200 ng for the detection of biotinylated Rev. Competition of the Rev-aptamer interaction was performed using RBE-coated beads and biotinylated HIV-Rev (50 nM) in the presence of increasing amounts of free RBE (0-1000 nM) or coumermycin A (0-100 µM) (Sigma-Aldrich). DMSO was used to dissolve coumermycin A, but the final concentration in the assay did not exceed 2% (v/v).
Detection of human α α-thrombin in human serum
Two thousand DNA15-coated beads were incubated with increasing amounts of human serum (0%-10% [v/v]) in a total volume of 50 µL thrombin binding buffer for 1 h in the dark at RT. For detection, 20 ng rabbit antihuman α-thrombin antibody (American Diagnostica, Stamford, CT) in 10 µL thrombin binding buffer was added to the assays and incubated for 1 h in the dark. Subsequently, 200 ng goat-antirabbit-Alexa 532 labeled antibody (Molecular Probes) in thrombin binding buffer was added to the assays and incubated for 1 h in the dark. The assays were analyzed as described above.
Compression assays
RBE-coated beads and biotinylated HIV-Rev (50 nM final concentration) were incubated with 4 different mixtures, each containing 3 different small-molecule inhibitors dissolved in DMSO, for 2 h in a total volume of 60 µL. The final assay concentration of each inhibitor was 50 µM, and final DMSO concentration was 2% (v/v). The makeup of each mixture was as follows: The fraction of bound protein was detected using 200 ng Strep-RPE as described above.
RESULTS
Interaction of human α α-thrombin with antithrombin aptamer
The 15-nucleotide antithrombin DNA aptamer DNA15 16 was modified with an amino linker at its 5´-end and covalently coupled to beads using EDC chemistry. Increasing amounts of biotinylated α-thrombin were incubated with DNA15-coated beads to test whether the functionality of the aptamer was influenced by immobilization on the bead surface. The bound fraction of α-thrombin was detected using SAPE ( Fig. 1A) . As a control, the same beads were incubated with biotinylated Sec7, a domain of Cytohesin-1, which is a guanosine 5´-diphosphate (GDP)/ guanosine 5´-triphosphate (GTP) exchange factor and thus is not expected to interact with DNA15. The phycoerythrin fluorescence associated with the DNA15-coated beads provided a direct measure of the amount of bound biotinylated protein. A concentrationdependent increase in fluorescence intensity was seen when αthrombin was titrated against the beads, whereas no interaction of Sec7 with the beads was detected ( Fig. 2A) . The apparent affinity of α-thrombin for DNA15 was in the low nanomolar range, in accordance with previous findings using fluorescence polarization (data not shown). This demonstrated that the DNA15 aptamer retained its ability to specifically interact with α-thrombin when coupled to beads.
Detection of α α-thrombin in human serum
The suitability of the aptamer/xMAP system for diagnostic applications was tested by investigating the ability of DNA15coated beads to detect unmodified α-thrombin in complex samples. Increasing amounts of human serum were added to DNA15-coated beads. α-Thrombin captured from serum was detected using a protein-specific primary and fluorescently labeled secondary antibody. A serum concentration of 0.125% (v/v) was sufficient to saturate the assay (Fig. 3A) . At serum concentrations greater than 1%, the detection antibodies were titrated out by excess α-thrombin. This result demonstrates that aptamer-coated beads can be used to specifically detect biomolecules in a complex sample (serum) and, hence, that they are suitable for diagnostic applications.
Competition of the α α-thrombin/DNA15 interaction
To further validate the specificity and reliability of the system, a competition assay was performed in which free unlabeled thrombin (in human serum) was added to a preformed complex between DNA15-coated beads and biotinylated thrombin. The displacement of biotinylated α-thrombin by unlabeled αthrombin from serum was followed by monitoring the decrease in SAPE fluorescence (Fig. 3B) . Almost complete displacement of biotinylated α-thrombin was observed at serum concentrations higher than 0.3125% (v/v).
The displacement assay was further developed to identify inhibitors that bind at the same site as the aptamer. Such an experimental setup is well suited for identification of smallmolecule ligands for target proteins. In being able to compete for the aptamer binding site, such ligands should display specific binding to and functional inactivation of the target of interest-both prerequisites for the development of a drug. We established a competition assay in which the disruption of the bead-bound DNA15-α-thrombin complex was induced by target-specific inhibitors (Fig. 1B) .
Hirudin fragment 54-65-the negatively charged C-terminal tail of the most potent known thrombin inhibitor, 19 which recognizes exosite I on thrombin 20 -and free DNA15 were used as competitors. As before, the displacement was followed by monitoring the decrease in detectable fluorescence of a preformed complex comprising bead-bound DNA15 and biotinylated α-thrombin. Both competitors were able to disrupt the bead-bound complex (Fig. 2) . A close-to-complete dissociation of the thrombin-aptamer complex was reached at a DNA15 concentration of 250 nM (Fig. 2B) . Hirudin fragment 54-65 was less effective in displacing α-thrombin from the DNA15coated beads, with concentrations of 7.5 µM being required for an 80% reduction in complex formation (Fig. 2C) .
Competition assays with the HIV-Rev RBE aptamer
To further test the applicability of aptamers as competitive screening probes, a second bead-based assay system was developed, in which the interaction between HIV-1 Rev and anti-Rev aptamer (RBE) was challenged in a competition assay using small-molecule inhibitors.
The anti-HIV-1 Rev aptamer RBE, which derives from the naturally occurring Rev-binding element from HIV-1, was coupled to beads. The functionality of immobilized RBE was verified by incubating RBE-coated beads with increasing amounts of biotinylated HIV-1 Rev protein. Bead-bound biotinylated Rev was measured using SAPE. A K d value of 13.2 ± 1 nM was determined from the corresponding binding curve (Fig. 4A) , when fitted to a 1-site binding model (Graph Pad Prism version 4.0), in close agreement to values obtained using fluorescence polarization measurements (data not shown). No binding of the biotinylated control protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to RBE-coated beads was observed (Fig. 4A) .
For competition experiments, RBE-coated beads saturated with Rev were incubated with increasing amounts of free RBE (Fig. 4B) or coumermycin A, an inhibitor of HIV-1 Rev (Fig.  4C ). 18 Both competitors were able to displace bound HIV-1 Rev from the RBE-coated beads in a concentration-dependent manner. Coumermycin A was found to be less effective in inhibiting complex formation of HIV-1 Rev with RBE than free RBE. Complete competition was achieved at a concentration of 50 µM coumermycin A.
Compound compression assay with HIV-1 Rev as target protein
A new trend in drug screening is to increase the density of an initial screen to save time and material. This can be achieved by either simultaneously screening more than 1 target per well or challenging the target with more than 1 compound per well. The latter method is termed compound compression (Fig.  1C) . 21, 22 An array of mixtures is generated in which each single compound is represented twice, following a unique distribution pattern. One mixture is then applied per well. Using this method enables a hit to be traced to a specific compound because inhibition must occur in both wells in which a mixture containing the relevant compound was present. We performed a basic compression assay using the HIV-1 Rev-RBE aptamer test system. Seven different small molecules (see Materials and Methods) were mixed in 4 different combinations to give a final concentration of 50 µM each in the assay. The HIV-1 Rev-RBE complex was disrupted by compound mixtures 2 and 3, both of which contained coumermycin A (Fig. 5) . It can be deduced that the other compounds in mixtures 2 and 3 have no influence on the interaction, as there was no competition detectable in mixtures 1 and 4, which also contained these compounds.
Using the compound compression assay, a Z´ factor of 0.8 and a coefficient of variability (CV) of 6.4% across the wells was achieved. Such values make this assay suitable for HTS 23 and demonstrate that aptamer-based xMAP assays are highly suitable for drug screening, even if their complexity is increased in a compression compound assay setup.
DISCUSSION
In recent years, genomic and proteomic projects have generated a huge number of potential protein targets. In many cases, little or nothing is known of these targets' biological function(s). To characterize and develop drugs for these targets, new screening technologies must emerge that-while focusing on target function-reduce assay development time and increase throughput. In addition, such assays should be sensitive, selective, robust, and cost-effective.
Due to the ease with which they can be chemically modified, aptamers have been used in a broad range of assay methods that are frequently used in HTS, such as fluorescence intensity (FI), fluorescence polarization (FP), fluorescence resonance energy transfer (FRET), and fluorescence lifetime (FLT). 24, 25 With these criteria in mind, we combined aptamer and beadbased xMAP technologies to develop novel assay systems for the detection of proteins in complex media and to screen for small-molecule inhibitors.
Aptamers specific for human α-thrombin or HIV-1 Rev were covalently coupled to beads and used as capture ligands for their respective targets. We demonstrated that neither affinity nor specificity of target-aptamer binding was influenced by the immobilization process. It is therefore assumed that the C6 (RBE) and C7 (DNA15) spacers that separated the aptamer sequence from the amino group (through which aptamers were coupled to the carboxy-functionalized bead surface) left enough 3-dimensional space for the aptamer to fold in the conformation required for specific target interaction.
DNA15-coated beads were used to detect α-thrombin in human serum. The detection method (a sandwich immunoassay) was analogous to that described by Drolet et al. 26 for the enzyme-linked immunosorbent assay (ELISA)-based detection of vascular endothelial growth factor (VEGF) in a serum sample. The thrombin assay was both specific and sensitive, allowing detection of α-thrombin in a serum dilution as low as 0.125%. Because normal α-thrombin concentration in serum is unknown, it is difficult to calculate a detection limit for our assay system, in which 1.9 nM primary antibody was present. Induction of thrombin generation is extremely localized by cascading coagulation reactions, and thus its concentration is subject to constant change. Prothrombin, the precursor of α-thrombin, is produced in the liver and can be found in blood at concentrations of approximately 1.2 µM. 27 However, this level can vary widely in normal individuals. 28 Furthermore, it is assumed that during blood clotting, not all prothrombin is processed to α-thrombin 29 and that most of the accumulated α-thrombin stays associated with the clot 28 and would therefore not be present in serum preparations. We can therefore presume that α-thrombin concentrations in serum would not exceed the initial 1.2-µM prothrombin concentration (corresponding to 1.5 nM in a 0.125% serum dilution).
Furthermore, a competition assay was designed that employed biotinylated α-thrombin precomplexed with DNA15-coated beads. Their ease of use and applicability for immunosensors or chromatographic strips 30 make such displacement assays very valuable. Compared to the direct capture assay described above, the competition assay has the advantage of not being reliant on the availability of specific primary antibodies for detection. This saves cost and simplifies the assay. However, purified and labeled target must be available to form the complex.
Importantly, the competition assay can as well be employed to screen for molecules that inhibit target function. Molecules that are able to displace the target from the aptamer are likely to form at least partly the same contacts with the target as the aptamer. Studies have shown that it is possible to identify small molecules that display biological activity against various target classes using aptamers as competitive screening probes. 15 Using α-thrombin as a target, we showed that the known thrombin inhibitor, hirudin fragment 54-65, was able to compete with DNA15 for the binding to thrombin exosite I. Thus, we demonstrate that it is possible to dissociate a protein from its aptamer with another site-specific ligand, even if the competing molecule is of lower affinity. Such functionality is a prerequisite for drug screening because small-molecule hits identified in primary screens typically have micromolar affinities for the target and therefore bind more weakly than aptamers. In a second system, we used the anti-HIV-1 Rev aptamer RBE to develop a competition assay similar to that developed for α-thrombin. We could demonstrate disruption of preformed HIV-1 Rev-RBE complexes using both free RBE and the known HIV-1 Rev inhibitor coumermycin A, identified by Hartig and coworkers, 18 who themselves applied an aptamer-based screening approach. The quality of the assay was controlled by the determination of the Z´ factor. This statistical coefficient, described by Zhang et al., 23 is an indicator for assay performance because it is reflective of both the assay signal dynamic range and the data variation associated with the signal measurements.
An assay suitable for screening should reach a Z´ factor > 0.5, with 1 being the reachable maximum value for assay reproducibility and reliability. The bead-based HIV-1 Rev-RBE assay achieved a Z´ factor of 0.8. The CV across the wells was determined to be 6.4%. We did not observe an effect on the HIV-1 Rev-aptamer interaction or the fluorescence signal output due to the presence of small amounts of DMSO in the assay. Coumermycin A-induced disruption of the interaction between HIV-1 Rev and RBE-coated beads was concentration dependent. The observed median of competition was below 20 µM, in close accordance with the findings of Hartig et al., 18 who obtained IC 50 values between 7 and 15 µM in their Rev-dependent ribozyme assays for coumermycin A. This shows that the HIV-1 Rev-RBE aptamer system is transferable to a bead-based approach without any appreciable loss in sensitivity. The high Z´ factor and low CV demonstrate the suitability of the bead-based competition assay for the screening of small-molecule inhibitors and its use in HTS applications. We tested the robustness of the assay system by adapting it to a multicompound compression screening approach. Such approaches streamline drug development by increasing throughput and decreasing unit cost while still accommodating growing compound libraries. 31, 32 Using the aptamer-based system, we were able to identify the inhibitor coumermycin A as the agent responsible for complex disruption in a screen using 4 separate mixtures, each containing 3 different compounds. This result demonstrates the robustness of the bead-based assay platform and its potential adaptability to highly complex assays.
The underlying principle of an xMAP measurement is the simultaneous detection of bead classification code and reporter fluorescence, which enables homogeneous multiplex assays. One could therefore envision a multiplex diagnostic assay in which several serum markers can be detected simultaneously using their respective aptamers, each coupled to a different bead set carrying a distinct bead color code.
The multiplexing capability of the xMAP system could also be applied to parallel analysis of several target-aptamer pairs immobilized on beads carrying different color codes. The combination of xMAP multiplexing with compound compression would significantly increase the density and efficiency of a screen. Such an approach would save time and reduce assay volumes, as well as subsequently save materials and reduce assay costs.
In this study, we have demonstrated proof of principle for several applications of aptamer-based xMAP assays. Given the adaptability, flexibility, and promise of aptamer and xMAP technologies, we are convinced that their combination will provide extremely powerful tools for diagnostics and drug discovery.
